Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen

Executive Summary

Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.

You may also be interested in...



Ribavirin ANDAs Clear FDA; Schering Goes Generic Too

Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol

Ribavirin ANDAs Clear FDA; Schering Goes Generic Too

Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol

Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration

Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments

Related Content

UsernamePublicRestriction

Register

PS038387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel